Calf-Guard

ZOETIS INC.
333 PORTAGE STREET, KALAMAZOO, MI, 49007
Telephone: 269-359-4414
Customer Service: 888-963-8471
Website: www.zoetis.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.
Calf-Guard®

Zoetis

Bovine Rota-Coronavirus Vaccine

Modified Live Virus

For veterinary use only

For vaccination of healthy newborn calves or pregnant cows as an aid in preventing diarrhea caused by bovine rotavirus and bovine coronavirus.

Directions: Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 3 mL without delay. Calves: Remove needle from syringe and administer a single 3-mL dose into the back of the calf’s mouth. Vaccination should occur as soon as possible after birth because susceptible calves are at risk as soon as they are born. Vaccination of calves older than 1 day may not be effective. Cows: Healthy cows should receive two 3-mL intramuscular doses administered 3-6 weeks apart during late pregnancy. Ideally, the second dose should be administered within 30 days prior to calving. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck. Historically, revaccination with two doses at each pregnancy has been recommended. The need for this booster vaccination has not been established for this product. For advice on revaccination frequency, contact your veterinarian.

Precautions: Store at 2°-8°C. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine. Inactivate unused contents before disposal. Do not vaccinate within 21 days before slaughter. Contains gentamicin as preservative. Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Management strategies based on vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy. Do not mix with other products, except as specified above. In case of human exposure, contact a physician.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (888) 963-8471 (USA), (800) 461-0917 (Canada).

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

VLN 190/PCN 1931.20

Zoetis Inc., Kalamazoo, MI 49007, USA

25 1-dose vials of vaccine, rehydrate each to 3 mL

25 3-mL vials of sterile diluent

40013962

CPN: 3690052.8